The Long Run with Luke Timmerman

Jeremy Levin, founder of Ovid Therapeutics and author of 'Biotech in the Balance,' discusses the systemic decline in public trust toward the biotechnology industry, tracing it from the Shkreli scandal through COVID-19 and into the current era of hostile policy. He argues the industry must recognize itself as strategically vital and offers ten commitments—including transparency, patient-centricity, and long-term capital formation—to rebuild its standing with the public and policymakers.